JonesTrading Sticks to Its Buy Rating for Satsuma Pharmaceuticals (STSA)

In a report released today, Sean Kim PhD from JonesTrading reiterated a Buy rating on Satsuma Pharmaceuticals (STSAResearch Report), with a price target of $14.00. The company’s shares opened today at $6.95.

According to TipRanks, Kim PhD is a 2-star analyst with an average return of -0.4% and a 36.36% success rate. Kim PhD covers the Healthcare sector, focusing on stocks such as Ocuphire Pharma, Concert Pharma, and CymaBay Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Satsuma Pharmaceuticals with a $12.60 average price target.

See Insiders’ Hot Stocks on TipRanks >>

The company has a one-year high of $7.00 and a one-year low of $2.51. Currently, Satsuma Pharmaceuticals has an average volume of 79.88K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It develops novel therapeutic products for the acute treatment of migraine. The company was founded by John Kollins on June 21, 2016 and is headquartered in San Francisco, CA.

Read More on STSA:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More